Abstract Body

Tuberculosis (TB) is a major cause of illness and death in people living with HIV (PLHIV). The World Health Organization recommends combining isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) to prevent TB. Due to potential increased hepatotoxicity in PLHIV with severe immunosuppression that are on IPT and ART, we evaluated its occurrence in this group.

We conducted a secondary analysis of A5274− a randomized clinical trial that enrolled ART naïve PLHIV from 10 resource limited countries. We restricted analysis to one arm of the trial where participants started IPT for 24 weeks within 7 days of ART. Eligible participants were ≥13 years; had CD4 counts <50 cells/μL and did not have active TB. Participants with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times upper limit of normal (ULN) were also eligible. Hepatotoxicity was defined as grade 3 (5.1–10.0 x ULN) or grade 4 (> 10.0 x ULN) AST or ALT or a diagnosis of hepatitis following initiation of IPT and ART. Raised pretreatment AST/ALT was defined as AST and/or ALT elevations at ≥1.25x ULN and <2.5xULN at study entry. Logistic regression was used to identify baseline risk factors for hepatotoxicity. Kaplan-Meier method was used to estimate the time to hepatotoxicity.

Among 426 participants− 53% male, median age 35 years, median CD4 count 19 cells/µL−31 (7.3%) developed hepatotoxicity. Twenty of these participants discontinued IPT; four of these later restarted and 11 participants did not discontinue IPT. Two participants with hepatotoxicity died from TB; one died from hairy cell leukemia. In multivariate analysis conducted on 410 participants without missing data, the significant risk factors for hepatotoxicity were raised pretreatment AST (OR 3.6, 95% CI 1.7-7.7) and positive HBsAg at baseline (OR 4.7, 95% CI 1.7-12.9). Participants who had both of these conditions at baseline (N=5/11) had a higher risk (OR 19.9, 95% CI 5.3-74.3) and earlier onset of hepatotoxicity than participants who had none of these conditions (N=12/298) (Figure 1A and 1B).

The incidence of hepatotoxicity during IPT and ART was high in this population. Severely immunosuppressed PLHIV with raised pretreatment AST/ALT or positive HBsAg at baseline should have targeted closer monitoring for hepatotoxicity. They should be considered for alternative TB preventive regimens such as use of intermittent rifapentine plus isoniazid or rifampicin plus isoniazid which are less hepatotoxic.